Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE2
Enrollment 37
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Propranolol is a drug that is classified as a beta-blocker. Beta-blockers affect the heart and circulation. Beta-blockers, like propranolol, may help to counteract effects of certain stress hormones produced by the body during cancer treatment and may increase the effectiveness of the pembrolizumab. Pembrolizumab is a drug that is classified as an immune checkpoint inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Propranolol may be able to re-sensitize the cells of the immune system to respond to the checkpoint inhibitor pembrolizumab in patients with checkpoint inhibitor refractory metastatic or unresectable triple negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Biological: Pembrolizumab — Given IV
  • Drug: Propranolol — Given PO
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Objective response (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-01
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 37 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Shipra Gandhi, MD, MS (PRINCIPAL_INVESTIGATOR) - Emory University Hospital/Winship Cancer Institute
Contact Information
Study Contact:
Shipra Gandhi, MD, MS
404-778-1900
shipra.gandhi@emory.edu
Kerry Dycus
404-727-2527
kerry.dycus@emory.edu
Emory University Hospital
Shipra Gandhi, MD, MS
Emory University Hospital
Interventions
  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Biological: Pembrolizumab — Given IV
  • Drug: Propranolol — Given PO
Study Locations (2 sites)
Emory University Hospital, Atlanta, Georgia 30322 United States
Roswell Park Cancer Institute, Buffalo, New York 14263 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 years of age * Have pathologically confirmed diagnosis of unresectable or metastatic triple negative breast cancer (TNBC) with no curative treatment options * No chemotherapy, radiotherapy, or major surgery within 4 weeks of protocol treatment * Checkpoint inhibitor refractory patients (i.e., no longer responding to chemotherapy and checkpoint inhibitor) who have disease progression on prior line of chemotherapy and pembrolizumab, and, who in the opinion of the physician, can continue checkpoint inhibitor * Patients must be agreeable to pre- and 6-week post treatment biopsy in part 1 of the study * The pre-treatment biopsy for this study must be taken at least 4 weeks after all previous chemotherapy (pembrolizumab is allowed during this period) * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g. hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =\< 1 * Platelets \>= 100,000/uL * Hemoglobin \>= 9.0 g/dL * Absolute neutrophil count (ANC) \>= 1500/uL * Total bilirubin =\< institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 X institutional ULN * Creatinine clearance \>= 50 mL/min per Cockcroft-Gault equation * HbA1C \<=8.5 * Have measurable disease per RECIST 1.1 criteria present * Ability to swallow and retain oral medication * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment * Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation * Patients with rapidly progressive disease/ symptomatic disease * Patients with primary resistance (i.e., did not respond to initial treatment with chemotherapy plus checkpoint inhibitor) with progressive disease at 12 weeks after starting chemotherapy and pembrolizumab * Patients who are pregnant or nursing. Women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening * Participants with symptomatic known brain metastases \< 4 weeks from radiation treatment should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastases or death * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Unwilling or unable to follow protocol requirements * Contraindications to the use of beta-blockers, like: uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (grade III or IV), hypotension (systolic blood pressure \< 100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), uncontrolled type I or type II diabetes mellitus (hemoglobin A1C \[HbA1C\] \> 8.5 or fasting plasma glucose \> 160 mg/dl at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current use of beta-blockers or non-dihydropyridine calcium channel blockers * Any additional condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the study drugs
Conditions Cardiotoxicity, Heart Failure, Neoplasms...
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure. Existing cardiovascular risk prediction scores have limited evidence in this setting. The ML-CardioTox study is a prospective, multicenter, observational cohort conducted in 15 centers in France. The primary objective is to develop a one-year prediction score for cancer therapy-related cardiotoxicity using machine learning methods. A dedicated software platform will be used to standardize data collection and support integration of artificial intelligence tools. A total of 600 patients treated with anthracyclines or HER2-targeted therapies in cardio-oncology clinics will be enrolled over a one-year inclusion period starting in December 2024, with a 12-month follow-up. The primary endpoint is the occurrence of cardiotoxicity as defined by the 2022 European Society of Cardiology guidelines (hospitalization for heart failure, initiation or escalation of diuretic therapy, decline in cardiac function on imaging, or increase in cardiac biomarkers such as troponin or natriuretic peptides). Secondary objectives include comparison of the predictive performance of the machine learning-derived score with the established HFA-ICOS risk score. Patients will be managed according to routine clinical practice. This study aims to improve prognostic stratification tools for patients receiving anthracyclines or HER2-targeted therapies, with the goal of better identifying those at high risk of developing cardiotoxicity during follow-up.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence of cardiotoxicity at 12 months (12 months after initiation of anthracycline or HER2-targeted therapy.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-29
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Caen
Contact Information
Study Contact:
Damien Legallois, MD, PhD
33231064418
damien.legallois@unicaen.fr
Damien Legallois, MD
+33231065118
CHU de Caen
Interventions
N/A
Study Locations (1 sites)
CHU de Caen, Caen, France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Planned follow-up in cardio-oncology clinic as part of a baseline pre-treatment evaluation before a sequence of anthracycline and/or HER2-targeted therapy, according to the 2022 ESC recommendations * Inclusion regardless of prior exposure to potentially cardiotoxic anticancer therapies or thoracic radiotherapy Exclusion Criteria: * Patients not covered by the French national health insurance system (Sécurité Sociale) * Patients for whom 12-month follow-up is planned outside the center performing the baseline pre-treatment evaluation
Conditions Hormone Receptor-Positive Breast Cancer,...
Phase PHASE2
Enrollment 393
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

* This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer. The study aims to determine if combining the CDK4/6 inhibitor Dalpiciclib with endocrine therapy can reduce the need for chemotherapy while maintaining clinical benefits. * Key Details : 1. Participants: 393 women (aged 18-75) with early-stage HR+/HER2- breast cancer at high risk of recurrence (e.g., tumor size ≥2 cm, lymph node involvement, or high-grade tumors). 2. Design: Patients are randomized 1:4 to two groups: Group A (Chemotherapy) : Receives 4 cycles of taxane-based chemotherapy before surgery. Group B (Experimental) : Receives Dalpiciclib + aromatase inhibitor (AI) for 4 cycles pre-surgery. Post-surgery, treatment is adjusted based on ctDNA results. 3. Primary Goals : Assess ctDNA clearance rate (conversion from detectable to undetectable ctDNA) after neoadjuvant therapy in Group B. Evaluate 3-year event-free survival (EFS) in Group B (e.g., freedom from cancer recurrence, progression, or death). Secondary Goals : Safety of Dalpiciclib + endocrine therapy. Tumor response rates (e.g., complete cell cycle arrest, pathological remission). Correlation between ctDNA clearance and long-term outcomes. * Why This Matters : Current guidelines recommend chemotherapy for high-risk HR+ breast cancer, but it often causes significant side effects. This study explores a personalized approach using ctDNA-a blood-based biomarker-to identify patients who may safely avoid chemotherapy without compromising survival. If successful, it could shift clinical practice toward less toxic, targeted therapies for eligible patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy — Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: (1)ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years; (2)ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to: * Arm B1: Dalpiciclib + ET for 2 years. * Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years;(3)Persistently ctDNA-positive or ctDNA-negative → positive: Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists.
  • Drug: Taxane-Based Neoadjuvant Chemotherapy — Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.

Primary Outcomes

  • ctDNA Clearance Rate after Neoadjuvant Therapy (From baseline to 4 weeks post-neoadjuvant therapy (pre-surgery))
  • 3-Year Event-Free Survival (EFS) (From randomization to 36 months post-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-08-01
Completion: 2029-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 393 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Principal Investigators:
  • shu wang, doctor (PRINCIPAL_INVESTIGATOR) - Peking University People's Hospital
Contact Information
Study Contact:
yuan peng, doctor
86+13671287670
13671287670@163.com
yuan peng, doctor
86+13671287670
13671287670@163.com
Peking University People's Hospital
Interventions
  • Drug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy — Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: (1)ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years; (2)ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to: * Arm B1: Dalpiciclib + ET for 2 years. * Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years;(3)Persistently ctDNA-positive or ctDNA-negative → positive: Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists.
  • Drug: Taxane-Based Neoadjuvant Chemotherapy — Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * Female breast cancer patients aged ≥18 years and ≤75 years, either postmenopausal or premenopausal/perimenopausal; * Pathologically confirmed hormone receptor-positive (HR+), HER2-negative invasive breast cancer: 1. ER-positive and/or PR-positive defined as: ≥10% of tumor cells showing positive staining; 2. HER2-negative defined as: standard immunohistochemistry (IHC) result of 0/1+; or IHC 2+ with negative in situ hybridization (ISH) (confirmed by the central pathology laboratory); * At least one evaluable lesion per RECIST 1.1, with clinical staging meeting: 1. T1c-2N0M0 with high-risk factors (Grade 3, or Grade 2 with Ki67 ≥20%); 2. T3N0M0; 3. Any TN+M0; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; * Willing to participate in the study and voluntarily sign informed consent; * Agree to undergo ctDNA testing during treatment; * Adequate organ and bone marrow function defined as: 1. Absolute neutrophil count (ANC) ≥1,500/mm³ (1.5 × 10⁹/L) (without granulocyte colony-stimulating factor \[G-CSF\] treatment within 14 days); 2. Platelet count (PLT) ≥100,000/mm³ (100 × 10⁹/L) (without corrective therapy within 7 days); 3. Hemoglobin (Hb) ≥9 g/dL (90 g/L) (without corrective therapy within 7 days); 4. Serum creatinine ≤1.5× upper limit of normal (ULN) or creatinine clearance ≥60 mL/min (without corrective therapy within 7 days); 5. Total bilirubin (TBIL) ≤1.5×ULN (without corrective therapy within 7 days); 6. Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤1.5×ULN (without corrective therapy within 7 days); 7. Cardiac function: left ventricular ejection fraction (LVEF) ≥55%; QTc interval corrected by Fridericia's formula (QTcF) \<470 msec on 12-lead ECG; * Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to use non-hormonal contraception from informed consent signing until 2 months after the last treatment. Exclusion Criteria: * HER2-positive breast cancer confirmed by current pathological diagnosis; * Inflammatory breast cancer; * Stage IV (metastatic) breast cancer; * Bilateral breast cancer; * Prior history of breast cancer (including ductal carcinoma in situ or invasive breast cancer); * Any prior antitumor therapy for the current breast cancer, including systemic therapies (endocrine, chemotherapy, immunotherapy, biological therapy) or local therapies (radiotherapy, vascular embolization, axillary lymph node biopsy); * Diagnosis of any malignancy within 5 years prior to randomization, except cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin; * History of severe pulmonary diseases (e.g., interstitial pneumonia); * HIV infection, acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥500 IU/mL), hepatitis C (HCV antibody-positive with HCV RNA above the lower limit of detection), or co-infection with HBV and HCV; * Within 6 months prior to randomization: myocardial infarction, severe/unstable angina, NYHA Class ≥II heart failure, ≥Grade 2 persistent arrhythmia (per NCI CTCAE v5.0), atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack), or symptomatic pulmonary embolism; * Severe active infection within 4 weeks prior to randomization (requiring intravenous antibiotics, antifungals, or antivirals) or unexplained fever \>38.5°C during screening/before first dose; * Known allergy to any component of the study drugs; * Current participation in another interventional drug clinical study; * Pregnancy or lactation; * Refusal to comply with follow-up; * Other severe physical/mental illnesses or laboratory abnormalities that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 3250
Locations 287 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence, as well as patient compliance and quality of life.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: ribociclib + AI ± LHRH — ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
  • Drug: abemaciclib + ET ± LHRH — abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
  • Drug: ET mono ± LHRH — endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Primary Outcomes

  • Invasive disease-free survival (iDFS) for adjuvant therapy with ribociclib + AI ± LHRH in participants with HR+/HER2- eBC at high risk of recurrence (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-20
Completion: 2030-06-30
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 3250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Drug: ribociclib + AI ± LHRH — ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
  • Drug: abemaciclib + ET ± LHRH — abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
  • Drug: ET mono ± LHRH — endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
Study Locations (287 sites)
Novartis Investigative Site, Wiener Neustadt, Lower Austria 2700 Austria
Novartis Investigative Site, Innsbruck, Tyrol 6020 Austria
Novartis Investigative Site, Linz, Upper Austria 4010 Austria
Novartis Investigative Site, Graz, 8036 Austria
Novartis Investigative Site, Klagenfurt, 9020 Austria
Novartis Investigative Site, Leoben, 8700 Austria
Novartis Investigative Site, Schwaz, 6130 Austria
Novartis Investigative Site, Steyr, 4400 Austria
Novartis Investigative Site, Vienna, 1090 Austria
Novartis Investigative Site, Vienna, 1130 Austria
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of HR+/HER2- early breast cancer with curative intent * Patients must have an indication for a treatment with ribociclib + AI ± LHRH as described in the current SmPC/"Fachinformation" of ribociclib (to be included into the cohorts of ribociclib + AI ± LHRH and ET mono ± LHRH) or abemaciclib + ET ± LHRH as described in the current SmPC/"Fachinformation" of abemaciclib (to be included into the abemaciclib + ET ± LHRH cohort) in the adjuvant setting * Before enrollment the treating physician has made the decision in accordance with the patient to treat the patient with either * ribociclib + AI ± LHRH, or * ET mono ± LHRH, or * abemaciclib + ET ± LHRH and baseline is no longer than 2 weeks (14 days) prior to written informed consent for this study. Baseline = for ribociclib + AI ± LHRH cohort: date of therapy start; for abemaciclib + ET ± LHRH cohort: date of therapy start; for ET mono ± LHRH cohort: within 4 weeks after therapy start or within 4 weeks after last non-endocrine based therapy, whichever is last. * ≥18 years of age * Written informed consent Exclusion Criteria: \- Patient is simultaneously participating in any investigational trial or simultaneously participating in another Novartis-sponsored non-interventional study with ribociclib.
Conditions Breast Cancer
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to demonstrate the feasibility of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: MR-Guided Focused Ultrasound Technology — MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
  • Drug: Definity Suspension for Injection — Microbubble contrast agents for ultrasound

Primary Outcomes

  • Safety profile of MRI- guided ultrasound stimulated microbubble treatment and radiation in patients with inoperable breast/chest wall tumours or LABC. (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-01
Completion: 2029-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Collaborators: Terry Fox Research Institute
Principal Investigators:
  • Gregory Czarnota, MD, PhD. (PRINCIPAL_INVESTIGATOR) - Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Gregory Czarnota, MD, Ph D.
+1 (416) 4806128
GregoyCzarnota@sunnybrook.ca
Gregory Czarnota, MD, PhD
+1 (416) 4806128
GregoryCzarnota@sunnybrook.ca
Sunnybrook Health Sciences Centre
Interventions
  • Device: MR-Guided Focused Ultrasound Technology — MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
  • Drug: Definity Suspension for Injection — Microbubble contrast agents for ultrasound
Study Locations (1 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * All biopsy-confirmed invasive ductal, invasive lobular and other rare histologic types of carcinoma. * Patients with early stage Breast cancer, or LABC ; i.e., Stage IIA - IIIC cancers (T2 N0 M0 to Any T, N3, M0) or Stage IV (Any T, Any N, M1) per AJCC guidelines (8th Edition). * Assessed as indicated, by a multidisciplinary team of treating medical, surgical and radiation oncologist and found suitable for radiation treatment. * Patient referred for standard palliative radiotherapy or curative radiotherapy, which may include (but are not limited to) any of the following dose regimens: 1) 5-8 Gy in one fraction, 2) 20 Gy in 5 fractions, 3) 30 Gy in 5 fractions, 4) 35 Gy in 5 fractions, 5) 30 Gy in 10 fractions, 6) 40 Gy in 10 fractions, 5) 50 Gy in 20 fractions, 6) 60 Gy in 30 fractions and 7) 66 Gy in 33 fractions, or radiobiologically similar doses. * Able to understand and give informed consent. * Weight \< 140 kg. * Target lesion accessible for MRg-FUS+MB procedure. * Able to communicate sensation during the procedure. * Creatinine within normal institutional limits or creatinine clearance \>60mL/min/ Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer. 1.73m2 for patients with creatinine levels above institutional upper limit of normal. Exclusion Criteria: * Pregnant or lactating women may not participate due to the embryotoxic effects of protocol treatment. * Unable to have a contrast-enhanced MRI scan - standard of care criteria. * Patients having received anthracycline or taxane based chemotherapy within the past 5 days. * Patients with metallic or breast implants. * Subjects with connective tissue disorder, musculoskeletal deformity. * Target lesion causing deep ulceration, bleeding or discharge of the overlying skin. * A fibrotic scar along the proposed FUS beam path. * Severe cardiovascular, neurological, renal or hematological chronic disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≥ 3. * Any condition that in the investigator's opinion precludes participation. * Unable to tolerate required stationary position during treatment. * Allergy to Definity microbubbles. * Cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker. * Contraindication to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation like cisapride, erythromycin, tricyclic antidepressants, Class IA and III antiarrhythmic agents and some antipsychotics like haloperidol, droperidol, quetiapine, thioridazine, ziprasidone. * Known QT prolongation = (QTc \> 450ms for men or \>470ms for women) with cardiac impairment if ECG is requested as per SOC. * History of bleeding disorder, coagulopathy. * Severely impaired renal function with estimated glomerular filtration rate \< 30ml/min/1.73m2 and/or on dialysis.
Conditions Metastatic Cancer, Metastatic Lung Cance...
Phase PHASE2
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: SBRT to the spine — Stereotactic body radiation therapy (SBRT) administered to spine metastases

Primary Outcomes

  • Cumulative incidence of spinal surgery/stabilization within 6 months following SBRT (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-12-14
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stony Brook University
Collaborators: The University of Texas Health Science Center at San Antonio
Principal Investigators:
  • Kartik Mani, MD PhD (PRINCIPAL_INVESTIGATOR) - Stony Brook Cancer Center
Contact Information
Study Contact:
Hermina Munoz, RN
631-216-2990
hermina.munoz@stonybrookmedicine.edu
Lucia Joya
631-216-2998
lucia.joya@stonybrookmedicine.edu
Caterina Vacchi-Suzzi, PhD
631-216-2993
caterina.vacchi-suzzi@stonybrookmedicine.edu
Stony Brook University Hospital
Interventions
  • Radiation: SBRT to the spine — Stereotactic body radiation therapy (SBRT) administered to spine metastases
Study Locations (1 sites)
Stony Brook University Hospital, Stony Brook, New York 11794 United States
Eligibility Criteria
Eligible patients must have: * Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease * Metastatic spine involvement documented by imaging * Involvement of maximum 3 contiguous vertebral bodies at the index site * Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids * An evaluation by an radiation oncology and orthopedic spine/neurosurgery attending * ECOG Performance Status of 0-3 Patients are ineligible if they have: * An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12 * Had previous surgery or radiation to address the target spinal metastases * Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)
Conditions Anatomic Stage II Breast Cancer AJCC v8,...
Phase PHASE3
Enrollment 3680
Locations 564 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo optional collection of tissue and/or blood
  • Drug: Cyclophosphamide — Given IV
  • Drug: Doxorubicin — Given IV
  • Biological: Durvalumab — Given IV
  • Other: Genetic Testing — Undergo MammaPrint testing
  • Procedure: Mammography — Undergo mammography
  • Drug: Paclitaxel — Given IV
  • Other: Quality-of-Life Assessment — Ancillary studies

Primary Outcomes

  • Breast cancer event-free survival (BC-EFS) (Up to 10 years after completion of study treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-11-27
Completion: 2032-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3680 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Erin F Cobain (PRINCIPAL_INVESTIGATOR) - SWOG Cancer Research Network
Contact Information
Study Contact:
Site Public Contact
gingerreeves@uabmc.edu
University of Alabama at Birmingham Cancer Center
Mauricio R. Escobar
University of Alabama at Birmingham Cancer Center
Site Public Contact
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org
Katmai Oncology Group
Interventions
  • Procedure: Biospecimen Collection — Undergo optional collection of tissue and/or blood
  • Drug: Cyclophosphamide — Given IV
  • Drug: Doxorubicin — Given IV
  • Biological: Durvalumab — Given IV
  • Other: Genetic Testing — Undergo MammaPrint testing
Study Locations (564 sites)
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States
Katmai Oncology Group, Anchorage, Alaska 99508 United States
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona 85704 United States
Banner University Medical Center - Tucson, Tucson, Arizona 85719 United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona 85719 United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas 72903 United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas 72401 United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
Sutter Auburn Faith Hospital, Auburn, California 95602 United States
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California 93301 United States
Eligibility Criteria
Inclusion Criteria: * STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines * NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible * STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer * NOTE: Participants with inflammatory breast cancer are eligible * NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node * STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines * STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer * STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions * NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biopsies should be pursued * STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status * Submitting tissue for on-study MammaPrint testing: * Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment * NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network OR * Submitting prior known MammaPrint Index Score: * If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy * NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to SWOG Cancer Research Network * NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study * NOTE: Participants enrolling with known MP2 status (i.e. MP already obtained as routine care) must only sign the treatment informed consent form. Screening consent is not required when MP2 status is known prior to study enrollment * STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy * STEP 1: REGISTRATION (SCREENING): Participants must be \>= 18 years old at the time of registration * STEP 1: REGISTRATION (SCREENING): Participants must have body weight \> 30 kg * STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2 * STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed * STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations * STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration * STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result * For participants submitting tissue for on-study MammaPrint testing: * Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) from initial tumor biopsy OR * Submitting commercial MammaPrint Index Score: * If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy * NOTE: Participants without a MammaPrint High-Risk 2 score must not be registered to Step 2 Randomization * STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed * STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study * STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2 * STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of a
Conditions Breast Cancer
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The investigators plan to carry out a phase II, open-label, single-arm clinical study of short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer, to explore whether 4 courses of dual HER2 blockade combined with taxanes can lead to a similar prognosis with current standard treatment, which is one-year trastuzumab monotherapy combined with chemotherapy, while reducing the adverse reactions of treatment.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pertuzumab — 4 cycles of taxane, pertuzumab, trastuzumab

Primary Outcomes

  • Disease free survival [DFS] (3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Xiaosong Chen
+8621-64370045*602102
chenxiaosong0156@hotmail.com
Yiwei Tong
+8621-64370045*602107
ash_yiwei@sjtu.edu.cn
Xiaosong Chen
+8621-64370045*602102
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Interventions
  • Drug: Pertuzumab — 4 cycles of taxane, pertuzumab, trastuzumab
Study Locations (1 sites)
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion Criteria: * Histologically diagnosed unilateral primary invasive breast cancer patient with pT1, pN0, and M0 disease * HER2-positive, ie. immunohistochemistry \[IHC\] 3+ or IHC 2+ and fluorescence in situ hybridisation \[FISH\]-positive according to ASCO/CAP 2018 guidelines * complete clinical pathological information * Eastern Cooperative oncology Group \[ECOG\] 0-1 * Currently not pregnant or breast-feeding * Fine organ function * Have good compliance with planned treatment, understand the study process and sign a written informed consent Exclusion Criteria: * Bilateral or metastatic breast cancer * Receiving neoadjuvant treatment * Other malignancies within 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer * Severe systemic infections or other serious illnesses * HIV infection, active hepatitis B or C infection * Known allergy to or intolerance to a therapeutic drug or its excipients * Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason * Enrollment of another investigational study within 4 weeks prior to initial administration of the investigational treatment * Receiving live vaccine within 30 days prior to initial administration of the investigational treatment * History of mental illness or drug abuse that may affect compliance with the trial requirements * The researchers determine that the patients were not suitable for the study
Conditions Metastatic Triple-Negative Breast Cancer
Phase PHASE1, PHASE2
Enrollment 31
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab govitecan — Given by IV
  • Drug: Naxitamab — Given by IV

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-09-19
Completion: 2030-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 31 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: Y-mAbs Therapeutics
Principal Investigators:
  • Clinton Yam, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Akshara S Raghavendra
713-792-2817
TNBC-NOW@mdanderson.org
Clinton Yam, MD
713-792-2817
TNBC-NOW@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Clinton Yam, MD
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Drug: Sacituzumab govitecan — Given by IV
  • Drug: Naxitamab — Given by IV
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion criteria * Male and female participants aged 18 years or older and able to understand and give written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (for the phase I portion of the study) and ECOG performance status of 0-2 (for the phase II portion of the study) * Life expectancy of at least 3 months * Histologically confirmed metastatic TNBC. (Estrogen receptor \[ER\] ≤10%; Progesterone receptor \[PgR\] ≤10%, HER2-negative as per ASCO/CAP guidelines) * Willingness to provide archival tumor tissue for correlative studies associated with this trial. * Received at least 1 prior line of systemic chemotherapy for metastatic TNBC and/or meet criteria to receive sacituzumab govitecan as standard of care * Measurable disease by CT or MRI as per RECIST Version 1.1 criteria * Adequate organ and marrow function as defined below: 2\. Exclusion Criteria Participants who meet any of the following exclusion criteria are not eligible to be enrolled in this study. * Positive serum pregnancy test or women who are lactating. * Known or severe (≥ Grade 3) hypersensitivity or allergy to naxitamab and/or sacituzumab govitecan, their metabolites, or formulation excipient. * Grade 3 or greater peripheral neuropathy * Have previously received treatment with an anti-GD2 antibody * Prior treatment with TROP2-targeting antibody drug conjugates in the metastatic setting. Participant s who have received TROP2-targeting antibody drug conjugates in the neoadjuvant setting or adjuvant setting are eligible if at least 6 months have elapsed since the last dose of TROP2-targeting antibody drug conjugate. * Have an active second malignancy. Participant s with a history of active cancer for 3 years prior to enrollment, or participant s with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll. * Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Have undergone an allogenic tissue or solid organ transplant. * Uncontrolled hypertension, defined as a consistently elevated systolic blood pressure of \>160 mmHg despite optimal medical management * Clinically significant cardiac disease * Inadequate pulmonary function * Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment. * Uncontrolled seizure disorders despite anticonvulsant therapy (defined as a seizure event within 3 months prior to enrollment) * Active serious infection requiring systemic antimicrobial therapy. * Participants positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. * Have active hepatitis B or C infection * Has a diagnosis of immunodeficiency or receiving systemic corticosteroid therapy (higher than physiologic doses) ≥ 10 mg of prednisone per day or equivalent\] or any other form of immunosuppressive therapy within 14 days of initiation of study treatment. * Has received prior radiotherapy within 1 weeks of start of study intervention.
Conditions Breast Cancer
Phase PHASE3
Enrollment 400
Locations 87 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: JSKN003 — Administered intravenously according to protocol.
  • Drug: Capecitabine tablets — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Gemcitabine hydrochloride for injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Vinorelbine tartrate injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Paclitaxel for injection (albumin-bound type) — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Docetaxel injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Eribulin mesylate injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).

Primary Outcomes

  • Progression Free Survival (PFS) (up to approximately 3 years after the first enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-01
Completion: 2029-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Principal Investigators:
  • Erwei Song (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Jiong Wu (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Erwei Song
020-81332507
songew@mail.sysu.edu.cn
Jiong Wu
02164175590
wujiong1122@vip.sina.com
Erwei Song
Erwei Song
Interventions
  • Drug: JSKN003 — Administered intravenously according to protocol.
  • Drug: Capecitabine tablets — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Gemcitabine hydrochloride for injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Vinorelbine tartrate injection — Administered according to protocol, as one option for investigator's choice (determined before randomization).
  • Drug: Paclitaxel for injection (albumin-bound type) — Administered according to protocol, as one option for investigator's choice (determined before randomization).
Study Locations (87 sites)
Erwei Song, Guangzhou, Guangdong China
Jiong Wu, Shanghai, Shanghai Municipality China
Anyang Cancer Hospital, Anyang, China
Affiliated Hospital of Hebei University, Baoding, China
Beijing Luhe Hospital, Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Peking University Cancer Hospital, Beijing, China
The First Affiliated Hospital of China Medical University, Beijing, China
The First Medical Center of the General Hospital of the People's Liberation Army Chinese People's Liberation Army, Beijing, China
Bethune First Hospital of Jilin University, Changchun, China
Eligibility Criteria
Inclusion Criteria: * 1\. The subject is able to understand the informed consent form, voluntarily participate and sign the informed consent form. 2\. The subject ≥ 18 years old on the day of signing the informed consent form, male or female. 3\. Unresectable locally recurrent or metastatic breast cancer, previous histopathological reports of HER2 IHC 1+ or 2+ and ISH-, previous histopathological reports have not been diagnosed as HER2 IHC 3+ or 2+ and ISH+. 4\. Have received at least 1 to 2 lines of chemotherapy regimens for breast cancer in the relapse/metastatic stage. 5\. Willing to provide sufficient archived tumor pathology specimens for central laboratory detection of HER2 status. 6\. Documented radiographic disease progression (during or after the most recent treatment). 7\. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria. 8\. Expected survival ≥ 3 months. 9. ECOG score of 0 or 1 within 14 days prior to administration. 10. Female subjects of childbearing potential or male subjects of fertile partner consent to use highly effective contraception from the signing of informed consent. 11\. Laboratory tests within 14 days before administration and cardiac function tests within 28 days meet the criteria. 12\. Have sufficient elution of previous treatment before administration. Exclusion Criteria: * 1\. Untreated, or unstable brain parenchymal metastases, spinal cord metastases or compression, cancerous meningitis. 2\. Patients with only skin lesions as target lesions. 3. Those with a history of other primary malignant tumors within 5 years before administration. 4\. Selection of the control drug by the investigator who is not suitable for the protocol prescribed. 5\. Previous use of antibody conjugates containing topoisomerase I inhibitors. 6. There is a third gap fluid that cannot be controlled by drainage, etc. 7. Previous or current interstitial pneumonia/lung disease requiring systemic hormone therapy. 8\. Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that affect oral administration and absorption of the drug. 9\. Previous or current autoimmune disease. 10. Have uncontrolled comorbidities. 11. The toxicity of previous antitumor therapy has not been restored to grade ≤1 (NCI-CTCAE v5.0). 12\. History of previous immunodeficiency. 13. History of life-threatening allergic reactions or known ≥ grade 3 allergy to any component or excipient in the investigational pharmaceutical formulation. 14\. Other conditions that the investigators believe will affect the safety or adherence to drug treatment in this study, including but not limited to psychiatric disorders, alcohol or drug abuse.
Conditions Hematological Toxicity, Targeted Therapy...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs. We plan to observe 1000 patients and collect data on treatment cycles N and N+1 of the targeted therapies. Retrospective data collection is based on existing patient diagnosis and treatment records, collecting information on patients who have completed two treatment cycles before January 1, 2024. Prospective data collection is based on routine clinical treatment during the study period, collected until the end of the next cycle of treatment or early termination of the study. To observe the disease characteristics and management mode of hematological toxicity related to targeted therapies of breast cancer, and explore the possible related factors of hematological toxicity, such as age, disease subtype, cancer stage, targeted therapy regimens, etc. This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: No intervenrion. — This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.

Primary Outcomes

  • Incidence of cancer treatment induced neutropenia (CIN) (Approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-15
Completion: 2027-06-10
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhi-Ming Shao (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhi-Ming Shao
+86-021-64175590
zhi_ming_shao@163.com
Peng Ji
+86-021-64175590
JIPENG_1010@163.COM
Zhi-Ming Shao
zhi_ming_shao@163.com
Zhi-Ming Shao
Interventions
  • Other: No intervenrion. — This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
Study Locations (1 sites)
Zhi-Ming Shao, Shanghai, Not US/Canada 200032 China
Eligibility Criteria
Inclusion Criteria: * · The patients signed the informed consent and voluntarily participated in the study. * A definite diagnosis of any type of breast cancer. * Receiving or has completed targeted therapies. * Investigator judged that the patient need to receive or had received treatment or prevention for CTIT, CIN or CRA induced by targeted therapies. Exclusion Criteria: * · Pregnant or lactating women. * Failure to understand the study or to obtain informed consent. * The investigator determined other situations that are not suitable for inclusion.
Conditions Type 2 Diabetes Mellitus (T2DM), Hypergl...
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center randomized controlled trial evaluating the efficacy and safety of short (3 days) versus long (10 days) courses of intermittent hypoxic-hyperoxic training (IHHT) in patients with type 2 diabetes mellitus aged 50-74 years. Participants will be randomized into three groups: 3-day IHHT course (n≥100), 10-day IHHT course (n≥100), or control group receiving gas mixture with constant O2 21% for 10 days (n≥50). The primary outcomes are fasting glucose levels and HbA1c. Secondary outcomes include cardiovascular parameters, quality of life, cognitive function, and biological age.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Intermittent Hypoxic-Hyperoxic Training (3 days) — Three daily sessions using HYPO-OXY-1 (OXYTERRA) device
  • Other: Intermittent Hypoxic-Hyperoxic Training (10 days) — Ten daily sessions using HYPO-OXY-1 (OXYTERRA) device
  • Other: Normoxic gas breathing — Ten daily sessions of breathing gas mixture with constant O2 21%

Primary Outcomes

  • Change in fasting glucose level (mmol/L) from baseline to 30±3 days after intervention completion (Baseline, day 30)
  • Change in HbA1c (%) from baseline to 30±3 days after intervention completion (Baseline, day 30)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-15
Completion: 2027-12-15
Eligibility
Age: 50 Years – 74 Years
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Medical Research Center for Therapy and Preventive Medicine
Principal Investigators:
  • Marina I Smirnova, PhD (STUDY_CHAIR) - National Medical Research Center for Therapy and Preventive Medicine
  • Svetlana A Berns, MD, Prof. (STUDY_CHAIR) - National Medical Research Center for Therapy and Preventive Medicine
  • Oksana M Drapkina, MD, Prof. (PRINCIPAL_INVESTIGATOR) - National Medical Research Center for Therapy and Preventive Medicine
Contact Information
Study Contact:
Mikhail G Chashchin, PhD
+79774331118
dr.chaschin@gmail.com
Oksana Drapkina
+7 (495) 212-07-13
National Medical Research Center for Therapy and Preventive Medicine
Interventions
  • Other: Intermittent Hypoxic-Hyperoxic Training (3 days) — Three daily sessions using HYPO-OXY-1 (OXYTERRA) device
  • Other: Intermittent Hypoxic-Hyperoxic Training (10 days) — Ten daily sessions using HYPO-OXY-1 (OXYTERRA) device
  • Other: Normoxic gas breathing — Ten daily sessions of breathing gas mixture with constant O2 21%
Study Locations (1 sites)
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
Eligibility Criteria
Inclusion Criteria: * Age 50-74 years inclusive * Type 2 diabetes mellitus confirmed by medical documentation * Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment * Ability to comply with study protocol requirements * Signed informed consent Exclusion Criteria: * Type 1 diabetes mellitus * Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma) * Acute or active chronic infections * Angina pectoris functional class III-IV * Uncontrolled grade 3 arterial hypertension (SBP ≥180 and/or DBP ≥110 mmHg) * Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months * Internal carotid artery stenosis \>60% and/or symptomatic stenosis 50-99% * Chronic obstructive pulmonary disease and bronchial asthma * Exacerbation and decompensation of chronic diseases within 1 month ALT and/or AST levels \>2-3 times upper limit of normal * Congenital heart and major vessel abnormalities * Implanted cardiac pacemaker * Cancer with remission \<5 years * Mental illness, drug addiction, alcohol dependence * Pregnancy * Inability to participate throughout the study period